GlassScriptPhysician profile
Richard S Tilson
NPI 1346336831
$16,013.91
in general payments reported to CMS, 2019-2025
31 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $2,525 · 2021: $7,916 · 2022: $440 · 2023: $1,118 · 2024: $1,905 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,898 · Travel and Lodging: $1,036 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,898.03 |
| Travel and Lodging | $1,035.66 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $9,740.00 | 2020-2021 | |
| Medtronic, INC. | $1,355.74 | 2022-2024 | Interstim |
| Abbvie INC. | $863.64 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Pfizer INC. | $584.62 | 2019-2025 | |
| Gilead Sciences, INC. | $557.27 | 2021-2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $525.00 | 2020 | |
| Genzyme Corporation | $335.60 | 2024-2025 | |
| Janssen Biotech, INC. | $314.75 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $290.73 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.29 | 2019-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $202.23 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $173.05 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $80.31 | 2025 | Voquezna |
| Organon LLC | $73.80 | 2024-2025 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $69.80 | 2022-2025 | Ocaliva |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $69.29 | 2024-2025 | Wegovy, Saxenda |
| Lucid Diagnostics INC. | $68.88 | 2024 | |
| Ironwood Pharmaceuticals, INC | $60.65 | 2024-2025 | |
| Neuraxis, INC. | $58.82 | 2025 | |
| Celgene Corporation | $55.22 | 2023-2024 | Zeposia |
| Alnylam Pharmaceuticals INC. | $48.88 | 2022-2024 | Givlaari |
| Merck Sharp & Dohme LLC | $48.51 | 2019-2024 | |
| Lilly USA, LLC | $39.06 | 2024-2025 | Omvoh |
| Steris Corporation | $32.71 | 2024 | |
| Ferring Pharmaceuticals INC. | $23.45 | 2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $19.99 | 2024 | Iqirvo |
| Sandoz INC. | $18.64 | 2023 | Hyrimoz |
| Biocon Biologics INC | $18.14 | 2024 | Hulio |
| Currax Pharmaceuticals LLC | $15.81 | 2025 | Contrave |
| Aimmune Therapeutics, INC. | $15.58 | 2025 | Zenpep |
| Amgen INC. | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Tilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.